Torrent Pharmaceuticals Ltd

Torrent Pharmaceuticals Annual General Meeting

Shareholders approved the appointment of Ms. Shanti Ekambaram as an Independent Director of Torrent Pharmaceuticals via Postal Ballot.

Torrent Pharmaceuticals Other Announcement

Torrent Pharmaceuticals Limited has been assigned an ESG rating of 70 by NSE Sustainability Ratings and Analytics Limited. This independent assessment follows SEBI's regulatory framework for ESG Rating Providers.

Torrent Pharmaceuticals Annual General Meeting

Torrent Pharmaceuticals issued a Postal Ballot notice to shareholders for the appointment of Shanti Ekambaram as an Independent Director. Voting concludes on September 6, 2026.

Torrent Pharmaceuticals Earnings Call Transcript: Key Takeaways

Torrent Pharma delivered strong Q1 performance with revenues up 55% following the JB Chemicals merger completion. EBITDA margins jumped to 33.8% driven by accelerated cost synergies.

Call

Guides 10% growth

Torrent Pharmaceuticals Other Announcement

Torrent Pharmaceuticals submitted a statement under Regulation 52(7) & (7A) regarding the utilization of issue proceeds for the quarter ended June 30, 2026.

Torrent Pharmaceuticals Q1 FY27 Results: Net Profit ₹566 Cr, Up 3.3% YoY

Torrent Pharmaceuticals Ltd reported revenue from operations of ₹4,921 Cr (+54.8% YoY) and net profit of ₹566 Cr (+3.3% YoY) for Q1 FY27.

Key figure

Net profit ₹566 Cr · +3.3% YoY

Torrent Pharmaceuticals Management Change

Torrent Pharmaceuticals appointed Shanti Ekambaram as an Additional Independent Director. The appointment is for a three-year term effective July 30, 2026.

Torrent Pharmaceuticals Merger & Restructuring

Torrent Pharmaceuticals allotted 4,19,22,416 equity shares to J.B. Chemicals shareholders. This allocation follows a Scheme of Amalgamation sanctioned by the NCLT.

Torrent Pharmaceuticals Merger & Restructuring Worth ₹1.3 Cr

Torrent Pharmaceuticals announced the voluntary dissolution of its Philippines-based subsidiary, Curatio Inc. The entity contributed Rs 1.3 Crore to the consolidated net worth.

Value

₹1.30 Cr

Torrent Pharmaceuticals Other Announcement

Torrent Pharmaceuticals received an ESG rating of 66 and a Core ESG rating of 74 from Crisil. These ratings assess the company's environmental, social, and governance performance.

Torrent Pharmaceuticals Board Meeting Date

Torrent Pharmaceuticals will hold a Board Meeting on July 30, 2026. The meeting will consider financial results for the quarter ended June 30, 2026.

Torrent Pharmaceuticals Adverse Business Impact

Torrent Pharmaceuticals initiated a voluntary recall for select batches of Semalix Injection Disposable Pens. The precautionary action follows a technical evaluation recall by manufacturer Dr. Reddy's.